Trial · NCT03038022
Outcomes25
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Percent Change in LDL-C From Baseline To Week 12 | Baseline up to Week 12 | Modified Intent-to-Treat (mITT) population: all participants who were randomized in the study, received at least 2 weeks of study drug, and had a valid lipid measurement at Week 2 or later. | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Change From Baseline to Week 12 of Free Thyroxine (T4) | Baseline up to Week 12 | Safety population: all participants who were randomized in the study and received at least 1 dose of study drug. | ng/dL | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Change From Baseline to Week 12 of Free Triiodothyronine (T3) | Baseline up to Week 12 | Safety population: all participants who were randomized in the study and received at least 1 dose of study drug. | ng/L | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Change From Baseline to Week 12 of Thyrotropin (TSH) | Baseline up to Week 12 | Safety population: all participants who were randomized in the study and received at least 1 dose of study drug. | mIU/L | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Change From Baseline to Week 12 of Thyroxine Binding Globulin (TBG) | Baseline up to Week 12 | Safety population: all participants who were randomized in the study and received at least 1 dose of study drug. | mg/L | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Change From Baseline to Week 12 of Reverse Triiodothyronine (T3) | Baseline up to Week 12 | Safety population: all participants who were randomized in the study and received at least 1 dose of study drug. | ng/dL | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 12 | Baseline up to Week 12 | percent change | LEAST_SQUARES_MEAN | |
| SECONDARY | Mean Percent Change In Triglycerides From Baseline To Week 12 | Baseline up to Week 12 | mITT population: all participants who were randomized in the study, received at least 2 weeks of study drug, and had a valid lipid measurement at Week 2 or later. | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Percent Change In Lipoprotein(a) (Lp[a]) From Baseline To Week 12 | Baseline up to Week 12 | mITT population: all participants who were randomized in the study, received at least 2 weeks of study drug, and had a valid lipid measurement at Week 2 or later. | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Percent Change in Apolipoprotein CIII From Baseline to Week 12 | Baseline up to Week 12 | percent change | LEAST_SQUARES_MEAN | |
| SECONDARY | Mean Percent Change In Apolipoprotein B (ApoB) From Baseline To Week 12 | Baseline up to Week 12 | mITT population: all participants who were randomized in the study, received at least 2 weeks of study drug, and had a valid lipid measurement at Week 2 or later. | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Percent Change in Apolipoprotein B/Apolipoprotein A1 (ApoB/ApoA1) Ratio From Baseline to Week 12 | Baseline up to Week 12 | percent change | LEAST_SQUARES_MEAN | |
| SECONDARY | Mean Percent Change In Cholesterol/HDL-C Ratio From Baseline to Week 12 | Baseline up to Week 12 | percent change | LEAST_SQUARES_MEAN | |
| SECONDARY | Absolute Change in LDL-C From Baseline to Week 12 | Baseline up to Week 12 | mg/dL | LEAST_SQUARES_MEAN | |
| SECONDARY | Percent Change From Baseline in LDL-C at Week 2 and Week 4 in Patients in the 100 mg and the 60 mg Groups | Baseline to Week 2 and Week 4 | percent change | LEAST_SQUARES_MEAN | |
| SECONDARY | Percent Change in LDL-C From Baseline to Week 12 by Systemic Exposure Category | Baseline to Week 12 | mITT Population | percent change | MEAN |
| SECONDARY | Mean Change in Lipid Particle Concentration From Baseline To Week 12: Total LDL Particles | Baseline up to Week 12 | nmol/L | LEAST_SQUARES_MEAN | |
| SECONDARY | Mean Change in Lipid Particle Concentration From Baseline To Week 12: Small LDL Particles | Baseline up to Week 12 | nmol/L | LEAST_SQUARES_MEAN | |
| SECONDARY | Mean Change in Lipid Particle Concentration From Baseline To Week 12: Intermediate LDL Particles | Baseline up to Week 12 | nmol/L | LEAST_SQUARES_MEAN | |
| SECONDARY | Mean Change in Lipid Particle Concentration From Baseline To Week 12: Large LDL Particles | Baseline up to Week 12 | nmol/L | LEAST_SQUARES_MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03038022/outcomes